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Abstract 
Background: Inflammatory bowel disease (IBD) is 
a term used to describe two conditions, Crohn’s 
disease and ulcerative colitis (UC), that currently 
have no definite cure. The incidence of IBD 
worldwide has increased, frequently affecting 
women during their reproductive years. 
Objectives: This study examines the association 
of Crohn's disease and ulcerative colitis (UC) with 
adverse pregnancy outcomes and looks at the 
interactions of race/ethnicity on these 
associations. 
Study Design: We examined hospital birth 
records in the National Inpatient Sample (NIS) 
data sets in 2011 and 2012. We identified 
maternal demographics and clinical 
characteristics using international classification of 
disease-9 codes. Chi-square and Fisher exact 
tests were used to examine associations and 
logistic regression models were used to control 
for confounders. 
Results: Crohn's disease is associated with small 
for gestational age, aOR 1.70(CI:1.53-
1.89,p<0.001) but not premature delivery, 
whereas UC was associated with prematurity, 
aOR 1.5(CI:1.36-1.66,p<0.001) to a greater 
extent than with SGA. Analyses by race/ethnicity 
showed Crohn’s disease to be associated with 
SGA among newborns of all racial groups, but 
most evident among African Americans, aOR 
2.55(CI:2.06-3.15,p<.001). Crohn’s disease was 
associated with prematurity only in Caucasian 
women, aOR 1.21(CI:1.10-1.34,p<.001). UC was 
associated with SGA newborns only in Hispanic 
mothers, aOR 3.40(CI:2.24-5.15,p<0.001), and 
with premature delivery only among Caucasian 
mothers, aOR 1.60(CI:1.42-1.80,p<.001). 
Conclusion: Both Crohn's disease and ulcerative 
colitis are associated with prematurity and small 
for gestational age in a way that is significantly 
affected by maternal race. Qualitative studies are 
needed to understand mechanisms for these 
associations and the role of race/ethnicity. 
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Introduction 
Crohn’s disease and ulcerative colitis 
(UC) are two chronic relapsing and 
remitting diseases that currently have no 
definitive cure and together compromise 
a class of conditions known as 
inflammatory bowel disease (IBD).1,2 In 
the United States, the incidence of 
Crohn’s disease has been 3.1 to 14.6 
cases per 100,000 person years and the 
prevalence is 201 per 100,000 adults, 
whereas the incidence of UC is 2.2 to 
14.3 cases per 100,000 person years 
and the prevalence is 238 per 100,000 
adults.1,2 IBD has long been considered 
a problem of Western societies due to 
certain lifestyle factors thought to 
contribute to its pathogenesis.3 However, 
data from recent years indicates that the 
incidence of IBD is on the rise worldwide, 
including in Eastern and developing 
countries.4,5 In addition, younger 
populations in industrialized urban 
societies are more frequently affected 
with IBD and, as a result, women during 
their reproductive years are affected.6 
Previous studies have linked maternal 
IBD with low birthweight, small for 
gestational age (SGA), and preterm 
delivery outcomes in neonates. 
However, these studies were either 
conducted outside of the United States7-
12 or were limited to a small sample 
size.13-16 In fact, a systematic review of 
past studies revealed inconsistencies in 
study size, quality and design, making it 
difficult to precisely assess the 
relationship between IBD and adverse 
birth outcomes.17-19 In addition, the 
relationship between IBD and race/ethnic 
groups with regard to adverse birth 
outcomes has not been previously 
addressed. Therefore, a study is needed 
to present data from across the United 
States taking into consideration 
race/ethnicity, in addition to other 
variables such as age, behavioral, 
socioeconomic and clinical 
characteristics.  
In this study we utilized the National 
Inpatient Sample (NIS) datasets, which 
include data from most states and 
regions of the United States. We 
examined the association between IBD in 
pregnant women and the risk for adverse 
birth outcomes. The specific aims of this 
study were to: 1) examine the association 
of Crohn’s disease in pregnant women 
with preterm delivery or SGA newborns 
while controlling for maternal 
demographic and clinical variables, 2) 
examine the association of UC with 
preterm delivery or SGA, and 3) examine 
the implication of maternal race/ethnicity 
on these associations. 
Methods 
Data Source 
We used de-identified datasets obtained 
from the Healthcare Cost and Utilization 
Project (HCUP) associated with the 
Federal Agency for Healthcare Research 
and Quality (AHRQ).20 The HCUP 
database is one of the largest healthcare 
databases in the United States that 
produces several datasets including the 
National Inpatient Sample (NIS). The NIS 
dataset is reproduced annually from an 
all-payer national database that has 
collected millions of inpatient 
hospitalization records from 1993 up to 
2012. These datasets have 
hospitalization records from more than 
1,000 hospitals across 45 states with 
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various care levels (primary–tertiary), 
types of insurance (public, private) and 
academic settings (university–general). 
Clinical data on hospitalization records 
are coded for each patient using 
International Classification of Disease - 
9th version (ICD-9). Current Procedural 
Terminology (CPT) are used to code 
surgical and non-surgical procedures 
done during patients’ hospitalizations. 
The NIS dataset includes more than 100 
data elements for each hospital stay, 
such as primary and secondary 
diagnoses, primary and secondary 
procedures, source of admission, 
disposition at discharge, patient 
demographics, expected payment 
source and total charges. 
Sample identification 
We included hospital records for 
pregnant women who gave birth to viable 
newborns in the years 2011 and 2012. 
We selected only these two years from 
the NIS data available from 1993-2012 to 
avoid multiple inclusions of same women 
with repeated pregnancies. Pregnant 
women who transferred out of the 
hospital of birth were excluded to avoid 
duplicate inclusion at both birthing and 
receiving hospitals. We used ICD-9 
diagnostic codes: 555, 5550, 5551, 5552, 
and 5559 to identify preexisting or 
recently diagnosed Crohn’s disease, and 
556, 5560, 5561, 5562, 5563, 5564, 
5565, 5566, 5568, and 5569 to identify 
preexisting or recently diagnosed UC in 
women admitted for birthing. Preterm 
delivery was identified when a live 
offspring was delivered before 
completing 37 weeks of gestation.21 We 
used ICD-9 diagnostic codes 6442, 
64420, and 64421 to identify preterm 
deliveries. Small for gestational age 
(SGA) was defined as birthweight below 
the 10th percentile.22 We used ICD-9 
diagnostic codes: 6565, 65650, 65651, 
and 65653 to identify small for 
gestational age newborns. We included 
potential demographic and clinical 
characteristics that may correlate with 
preterm delivery or SGA outcomes in our 
analysis as potential confounding factors 
using respective ICD-9 codes. 
Confounders included maternal age, 
race, hypertension, cardiovascular 
diseases, diabetes mellitus, renal 
diseases, anemia, thyroid diseases, 
chorioamnionitis, coagulation disorder, 
seizures, obesity, smoking or drug 
abuse, placenta previa, placental 
abruption, twin gestation and type of 
insurance coverage.  
Statistical analysis 
We used a retrospective cross-sectional 
study design to run this analysis. We 
identified two main groups in the sample, 
pregnant women with or without IBD. We 
created two subgroups for those with or 
without Crohn’s disease and those with 
or without UC. We used SAS 9.1 (SAS 
Institute, Cary, NC, USA) to run our 
statistical analysis. We used frequency 
analyses to calculate prevalence of 
inflammatory bowel diseases, Crohn’s 
disease, UC, adverse birth outcomes 
(preterm delivery and SGA newborns), 
and other demographic and clinical 
characteristics in each group and 
subgroup. We calculated unadjusted 
odds ratios (ORs), 95% Confidence 
Intervals (CI) and p-value for all 
demographic and clinical variables for 
both IBD groups using Chi-square and 
Fisher exact tests. Logistic regression 
models were used to calculate adjusted 
ORs for the association of IBD (and 
subsequently for both Crohn’s disease or 
UC) with preterm delivery and SGA 
status while controlling for the 
demographic and clinical characteristics 
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mentioned above. Furthermore, adjusted 
ORs examining the association of 
Crohn’s disease and UC with preterm 
delivery and SGA were calculated within 
each race/ethnicity. We considered p-
value to be statistically significant if it was 
< 0.05. This study was conducted with 
Internal Review Board (IRB) approval 
from the George Washington University 
Hospital. 
Results 
The weighted data set included 
8,273,987 pregnant women with the 
following racial/ethnic distribution: 47.9% 
White, 14.0% African American, 20.3% 
Hispanic. Pregnant women ages 13-17 
years old represented 2.5% of the 
sample while women >35 years old 
represented 14.8%. ICD-9 diagnostic 
codes for IBD were identified in 14,476 
(0.18%) hospital discharge records; 
(Crohn's disease in 0.11% and UC in 
0.07% of the population). Preterm 
delivery occurred in 6.08% of the cases 
and 2.34% delivered SGA newborns. 
Data for the study include the following 
generalizations. Pregnant women with 
IBD were mostly white (69.4%). IBD was 
less common in teenage mothers (0.6% 
vs 2.5%, p<0.001) but more frequent in 
pregnant women > 35 years old (18.1% 
vs. 14.8%, p<0.001). Pregnant women 
with IBD were more frequently identified 
with cardiovascular, renal, thyroid, 
anemia, seizure and coagulation 
disorders as well as with a higher 
prevalence of placental abruption, and 
increased alcohol or drug abuse. 
However, pregnant women with IBD 
were less likely to be obese, have 
chorioamnionitis or be covered by public 
insurance. Table (1) shows frequencies, 
percentages and adjusted odds ratios 
(aOR) for the demographic and clinical 
characteristics of the study population. 
Figure 1 demonstrates the association of 
preterm delivery and SGA newborns with 
IBD and its subtypes (Crohn’s disease 
and UC) in the overall population after 
adjusting for confounding variables.   
IBD is associated with preterm delivery, 
aOR 1.24 (CI: 1.17-1.33, p<0.001), and 
small for gestational age, aOR 1.57 
(CI:1.44-1.71, p<0.001). Further analysis 
of each of the IBD subtypes, Crohn’s 
disease and UC, revealed significant 
differences in the association of each 
disease with the examined birth 
outcomes. Crohn's disease was not 
generally associated with preterm 
deliveries, but was significantly 
associated with SGA, aOR 1.70 (CI: 
1.53-1.89, p<0.001). In contrast, UC was 
more likely to be associated with preterm 
deliveries, aOR 1.50 (CI: 1.36-1.66, 
p<0.001) than with SGA, aOR 1.31 (CI: 
1.08-1.59, p=0.001) after adjusting for 
demographic and clinical confounders in 






 Proceedings in Obstetrics and Gynecology, 2020;10(1):3 
Maternal IBD and adverse birth outcomes  5 
Table 1: Demographic and clinical characteristics of pregnant women with and 
without inflammatory bowel disease (IBD)* 
  Women with 
IBD, n (%) 
n=14,476 
Women without 
IBD, n (%) 
n=8,355,987 
Adjusted OR (CI), p-value 
Maternal age groups 













0.34 (0.27 – 0.41), p<.0001 





















0.60 (0.57 – 0.64), p<.0001 
0.24 (0.22 – 0.25), p<.0001 
0.14 (0.12 – 0.17), p<.0001 
0.30 (0.22 – 0.40), p<.0001 
Twin gestation 315 (2.2) 115,387 (1.4) 1.25 (1.12 – 1.40), p<.0001 
Hypertension 1559 (10.8) 851,730 (10.3) 0.96 (0.91 - 1.02), p=0.161 
Chorioamnionitis 108 (0.8) 75,869 (0.9) 0.79 (0.65 - 0.95), p=0.014 
Diabetes mellitus 169 (1.2) 107,116 (1.3) 0.93 (0.80 - 1.08), p=0.330 
Cardiovascular diseases 243 (1.7) 56,783 (0.7) 1.95 (1.71 - 2.21), p<0.001 
Renal diseases 719 (5.0) 209,776 (2.5) 2.06 (1.91 - 2.22), p<0.001 
Maternal anemia 2801 (19.4) 988,773 (12.0) 1.94 (1.86 - 2.02), p<0.001 
Thyroid diseases 702 (4.9) 238,269 (2.9) 1.35 (1.25 - 1.46), p<0.001 
Seizure disorders 138 (0.95) 34,461 (0.42) 2.07 (1.75 – 2.45), p<0.001 
Coagulation disorders 323 (2.23) 119,837 (1.45) 1.25 (1.12 – 1.40), p<0.001 
Placenta previa 100 (0.7) 55,531 (0.7) 0.86 (0.71 - 1.05), p=.158 
Placental abruption 197 (1.4) 86,192 (1.0) 1.22 (1.06 - 1.40), p=.007 
Obesity 577 (4.0) 403,819 (4.9) 0.79 (0.73 – 0.86), p<0.001 
Smoking 912 (6.3) 441,590 (5.4) 1.04 (0.97 – 1.11), p<0.339 
Alcohol use 20 (0.14) 3154 (0.04) 3.28 (2.11 – 5.10), p<0.001 
Drug use 166 (1.15) 39,755 (0.48) 1.94 (1.66 – 2.27), p<0.001 
Public insurance 4036 (27.9) 3,738,911 (45.3) 0.55 (0.53 – 0.57), p<0.001 
Preterm Delivery 1099 (7.59) 501,717 (6.07) 1.24 (1.17 - 1.33), p <0.001 
Small for Gestational Age 541 (3.74) 193,344 (2.34) 1.57 (1.44 - 1.71), p <0.001 
 
*Confounding variables controlled for in the logistic regression model for the weighted sample included maternal age, 
race, hypertension, cardiovascular and renal diseases, diabetes mellitus, anemia, thyroid disorders, chorioamnionitis, 
coagulation disorder, seizures, obesity, smoking or drug abuse, placenta previa, placental abruption, twin gestation 
and type of insurance coverage 
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Figure 1: Preterm delivery and small for gestational age (SGA) in pregnant women 
with and without inflammatory bowel disease (IBD) in Figure 1A, Crohn’s disease 


















































No UC* p <0.001
* p =0.001
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The analysis was repeated separately 
controlling for race/ethnicity. In general, 
the impact of Crohn’s disease on 
pregnancy outcomes was different from 
that of UC within each race/ethnicity. 
Although, Crohn’s disease was not 
associated with preterm delivery in the 
overall sample, it was significantly 
associated with preterm delivery among 
White women, aOR 1.21 (CI: 1.10-1.34, 
p<.001). Crohn’s disease was associated 
with increased SGA among newborns of 
all three racial groups, with the greatest 
association observed among African 
Americans, aOR 2.55 (CI: 2.06-3.15, 
p<.001), (Figure 2).  
 
 
Table 2: Adverse birth outcomes associated with Crohn’s disease* 







Preterm delivery among women with Crohn's disease compared to those without 
Overall sample 6.76 6.08 1.09 (1.00-1.19) p = 0.05 
White 7.01 5.6 1.21 (1.10-1.34) p <0.001 
African American 7.18 8.08 0.87 (0.70-1.10) p = 0.23 
Hispanic 4.87 6.02 0.66 (0.41-1.06) p = 0.09 
Small for gestational age among women with Crohn's disease compared to those without 
Overall sample 4.17 2.34 1.70 (1.53-1.89), p <0.001 
White 3.26 2.34 1.38 (1.20-1.59), p <0.001 
African American 7.92 3.27 2.55 (2.06-3.15), p <0.001 
Hispanic 3.69 1.58 (1.14-3.34), P = 0.015 
 
*Confounding variables controlled for in the logistic regression model for the weighted sample included 
maternal age, hypertension, cardiovascular and renal diseases, diabetes mellitus, anemia, thyroid 
disorders, chorioamnionitis, coagulation disorder, seizures, obesity, smoking or drug abuse, placenta 
previa, placental abruption, twin gestation, and type of insurance coverage 
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Figure 2: Preterm delivery and small for gestational age (SGA) among pregnant 
women with and without Crohn’s disease and ulcerative colitis (UC) in different 
race/ethnic groups. Figures 2A and 2B compare preterm delivery and SGA 
between Whites, African Americans, and Hispanics with Crohn’s disease, 
respectively. Figures 2C and 2D compare preterm delivery and SGA between 
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Although UC was associated with 
preterm delivery in the overall sample, it 
was in fact, found to be closely 
associated with preterm delivery only 
among White women, aOR 1.60 (CI: 
1.42-1.80, p<.001). No significant 
association of UC with preterm delivery 
was noted among African American or 
Hispanic women. SGA newborns, on the 
other hand, were more common in 
women with UC among both Hispanic 
and White pregnant women, with a much 
greater association observed among 
Hispanics, aOR 3.40 (CI: 2.24-5.15, 
p<0.001) than among Whites. In 
contrast, African American women with 
UC delivered fewer SGA newborns than 
women with no UC, aOR 0.33 (CI: 0.13-
0.83, p=0.019), (Figure 2). 
Table 3: Adverse birth outcomes associated with ulcerative colitis (UC)* 
  Women with UC 
(%) 
Women without UC 
(%) 
Adjusted OR (CI), p-value 
Preterm delivery among women with ulcerative colitis  
Overall sample 8.95 6.08 1.50 (1.36-1.66) p <0.001 
White 9.19 5.6 1.60 (1.42-1.80) p <0.001 
African American 6.95 8.08 0.90 (0.62-1.32) p = 0.60 
Hispanic 6.54 6.02 1.09 (0.74-1.60) p = 0.66 
Small for gestational age among women with ulcerative colitis compared to those without 
Overall sample 3 2.34 1.31 (1.08-1.59) p = 0.001 
White 2.87 2.34 1.28 (1.04-1.54) p = 0.007 
African American 1.07 3.27 0.33 (0.13-0.83) p = 0.019 
Hispanic 5.31 1.57 (2.24-5.15) p <0.001 
*Confounding variables controlled for in the logistic regression model for the weighted sample included 
maternal age, hypertension, cardiovascular and renal diseases, diabetes mellitus, anemia, thyroid 
disorders, chorioamnionitis, coagulation disorder, seizures, obesity, smoking or drug abuse, placenta 
previa, placental abruption, twin gestation, and type of insurance coverage 
 
Discussion 
Principal Findings  
This study demonstrated significant 
increase in preterm delivery and SGA 
newborns among pregnant women with 
IBD after adjusting for clinical 
confounders known to increase the 
likelihood of both adverse birth 
outcomes. The associations of preterm 
delivery with both Crohn’s disease and 
UC were only evident among the White 
population. However, SGA was 
associated with both diseases in all races 
except African Americans with UC.   
Results 
IBD was associated with both premature 
delivery and SGA. Previous studies have 
reached different conclusions; some 
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studies indicated an association between 
prematurity and SGA birth with IBD, while 
other studies have found no such 
association in one or both of the IBD 
subtypes.23-28  A meta-analysis by 
Cornish et al., which included data from 
12 studies on 3,907 patients with IBD and 
320,531 subjects without IBD, found that 
women with IBD had increased risk of 
preterm delivery, but not of SGA birth.14 
A meta-analysis by O’Toole et al., which 
included data from 23 studies on 15,007 
patients with IBD and 4,614,271 subjects 
without IBD, found that women with IBD 
had a significantly increased risk for both 
preterm delivery and SGA. Although 
findings of this meta-analysis were like 
ours, we observed a stronger association 
with SGA birth than with preterm delivery. 
Moreover, we stratified outcomes 
according to IBD subtypes and controlled 
for several potential confounding factors.   
To the best of our knowledge, this study 
is the first to assess birth outcome risks 
in IBD population stratified by race/ethnic 
groups. In Whites, both Crohn’s disease 
and UC were associated with premature 
birth and SGA newborn outcomes, 
showing the most significant association 
for UC with preterm deliveries. In African 
Americans, neither Crohn’s disease nor 
UC was associated with preterm delivery. 
Meanwhile, the association of both IBD 
subtypes differed in relation to SGA 
newborn outcomes. Crohn’s disease was 
associated more with SGA, while UC was 
associated less with SGA. These 
paradoxical findings need further 
qualitative studies to understand the 
underlying cultural, nutritional or 
psychological factors. In Hispanics, 
association with premature birth was not 
increased with either Crohn’s disease or 
UC, but association with SGA newborns 
increased with both diseases, with a 
stronger association between UC and 
SGA. Unlike preterm delivery, SGA was 
associated with both Crohn’s disease 
and UC in each of the race/ethnic 
subgroups: Whites, African Americans 
and Hispanics.  However, the nature and 
magnitude of these associations differed 
according to both the disease (Crohn’s 
disease vs. UC) and race. In Crohn’s 
disease, the greatest association with 
SGA was seen in African Americans 
followed by Hispanics, then Whites. In 
UC, SGA was mostly associated with 
Hispanics followed by Whites.  
Clinical Implications 
Although the exact etiology of IBD 
remains unclear, several factors 
including genetics and environment are 
thought to be involved. Microorganisms 
such as bacteria and viruses, and 
sensitivity to protein in foods have been 
linked to these conditions.29-32 In addition 
to its inflammatory effect at the maternal 
fetal interface, Crohn’s disease or 
resection of small bowel as treatment for 
Crohn’s disease may interfere with 
gastrointestinal absorption of nutrients 
that could compromise transfer of micro- 
and macro-nutrients from mother to fetus 
leading to increased risk of SGA birth.32 
Furthermore, patients who are very ill 
with active Crohn’s disease and UC and 
who do not respond to medical therapy 
may have reduced food consumption. In 
addition, IBD is associated with innate 
immune deficits including those of toll-
like receptor (TLR) signaling and NOD-
like receptor signaling in addition to 
deficiency of defensins and autophagy 
pathways.33 These defects are likely 
involved in the abnormal mucosal 
response seen in IBD, but TLR 
irregularities are also hypothesized to 
cause delivery-inducing release of pro-
inflammatory cytokines and 
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prostaglandins in response to microbial 
stimuli. Another theory is that the role of 
increased gut permeability during 
increased inflammation could alter 
nutritional and immunological factors 
affecting delivery.30 
The increased perinatal morbidity in 
patients with Crohn’s disease and UC 
could be due in part to a variety of extra- 
intestinal manifestations of IBD, 
especially inflammatory conditions of the 
liver and joints, and arterio-venous 
thromboembolic pathologies. These 
inflammatory disorders have genetic 
correlates, notably that human leukocyte 
antigens and their pathogenesis include 
T-cell activity and that imbalances in 
cytokine production and intestinal 
antigens are shared by other organs.28-33 
The association of preterm delivery with 
Crohn’s disease and UC is plausibly 
related to such mechanisms that are 
common in both subtypes of IBD. More 
qualitative and delivery-related studies 
are needed to understand the underlying 
mechanisms (genetic, environmental, or 
biological) of adverse neonatal outcomes 
in women with IBD. 
This study can increase the awareness of 
health care providers with regard to the 
differential impact of each subtype of 
IBD; Crohn’s disease and UC, on birth 
outcomes, and can, therefore, enable 
them to offer more specific counseling 
and comprehensive clinical care to 
pregnant women according to their 
specific illness. Such tailored counseling 
would be provided according to maternal 
race/ethnic background. For example, 
pregnant women with Crohn’s disease 
could be counseled for their increased 
risk of small for gestational age 
outcomes, especially those of African 
American or Hispanic descent. White 
women with ulcerative colitis could be 
counseled for their increased risk of 
prematurity, while those of Hispanic 
origin could be counseled for their 
increased risk for small for gestational 
age. In this way, health care providers 
would be able to enhance their 
monitoring for early signs of fetal growth 
restriction or preterm labor according to 
each peculiarities of each disease and 
within each race/ethnicity respectively. 
Research Implications 
Future research on the association of 
maternal IBD with adverse neonatal 
outcomes should focus on analyzing the 
impact of additional predictors for 
prematurity and SGA. Our study stratified 
odd ratios according to maternal race, 
but additional stratification according to 
maternal age, neonatal sex or clinical 
conditions could also be performed. In 
addition, risk factors common to both 
preterm and SGA birth, such as low 
weight gain during pregnancy, maternal 
short stature and maternal stress level, 38 
could be analyzed in future studies for 
their impact on women with IBD.     
Strengths and limitations 
This study benefited from several 
strengths. Foremost, the study was 
conducted using a national in-hospital 
dataset while previous studies were 
limited to small samples or to state-
limited datasets.  The NIS database has 
the following unique merits: (1) it is one 
of the largest databases in the United 
States and may therefore represent the 
true diversity of the population allowing 
for study of relatively rare conditions such 
as Crohn’s disease and UC; (2) the NIS 
dataset includes several clinical and 
demographic variables that have ICD-9 
diagnostic codes and that were reported 
by physicians during admission or upon 
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discharge, hence, providing information 
on risk factors not included in previous 
studies; and (3) under-
representation/under-reporting for some 
of the variables of interest may be 
assumed to be equally distributed among 
groups and, therefore, associations are 
still valid.  
However, certain limitations were also 
observed in this study. Although using a 
national database that identified specific 
ICD-9 diagnostic codes for premature 
delivery and SGA, it is difficult to account 
for variability in the diagnostic practices 
of physicians. In addition, the study was 
limited by the inability to identify some 
demographic characteristics such as 
socioeconomic status, which was shown 
to associate with SGA and prematurity.37 
To overcome such limitation, we 
controlled for type of insurance as an 
indirect indicator for socioeconomic 
status. As HCUP data is a de-identified 
dataset, we could not link between the 
babies’ records and those of their 
mothers. However, all relevant maternal 
conditions (including IBD subtypes) are 
provided as ICD9 codes, along with 
several factors related to their offspring 
such as prematurity and small for 
gestational age. Data about dietary 
behaviors, level of education, or 
psychological confounders were not 
documented and could not be controlled 
for in the logistic regression models. The 
difficulty in assessment is further 
compounded by the fact that many of the 
medications used to treat IBD could be 
associated with preterm delivery,18 
although it is believed that the greatest 
risk to adverse outcomes is due to active 
disease and not active therapy.19 
Furthermore, using ICD codes to assess 
for the presence of Crohn’s disease or 
UC did not allow us access to information 
about disease activity during pregnancy. 
Any active inflammation during 
pregnancy can be associated with 
negative birth outcomes. Disease activity 
may be confounded by medication use, 
race/ethnicity and other unknown 
confounders. Finally, we could not 
explain the higher prevalence of alcohol 
and drug use among pregnant women 
with IBD in this sample. These findings 
may be the result of surveillance bias, or 
it may be that such diseases may be 
accompanied by mental health disorders 
and vulnerability to addiction. 
Conclusion 
This study supported the assertion that 
IBD was associated with preterm and 
SGA birth; however, risk disparities 
existed among race/ethnic groups and 
IBD subtypes. These findings could be a 
valuable resource for clinicians while 
counseling pregnant women about 
differences in race/ethnicity and IBD 
subtype. Further qualitative studies are 
warranted to explain variability of 




1. Loftus EV Jr. Clinical epidemiology of 
inflammatory bowel disease: Incidence, 
prevalence, and environmental 
influences. Gastroenterology. 2004 
May;126(6):1504-17. 
https://doi.org/10.1053/j.gastro.2004.01.
063 PMID: 15168363. 
 Proceedings in Obstetrics and Gynecology, 2020;10(1):3 
Maternal IBD and adverse birth outcomes  13 
2. Kappelman MD, Rifas-Shiman SL, 
Kleinman K, Ollendorf D, Bousvaros A, 
Grand RJ, Finkelstein JA. The 
prevalence and geographic distribution 
of Crohn's disease and ulcerative colitis 
in the United States. Clin Gastroenterol 
Hepatol. 2007 Dec;5(12):1424-9. 
https://doi.org/10.1016/j.cgh.2007.07.01
2 Epub 2007 Sep 29. PMID: 17904915. 
3. Bernstein CN, Shanahan F. Disorders of 
a modern lifestyle: reconciling the 
epidemiology of inflammatory bowel 
diseases. Gut. 2008 Sep;57(9):1185-91. 
https://doi.org/10.1136/gut.2007.122143 
Epub 2008 May 30. PMID: 18515412. 
4. Goh K, Xiao SD. Inflammatory bowel 
disease: a survey of the epidemiology in 
Asia. J Dig Dis. 2009 Feb;10(1):1-6. 
https://doi.org/10.1111/j.1751-
2980.2008.00355.x PMID: 19236540. 
5. Molodecky NA, Soon IS, Rabi DM, Ghali 
WA, Ferris M, Chernoff G, Benchimol EI, 
Panaccione R, Ghosh S, Barkema HW, 
Kaplan GG. Increasing incidence and 
prevalence of the inflammatory bowel 
diseases with time, based on systematic 
review. Gastroenterology. 2012 
Jan;142(1):46-54.e42; quiz e30. 
https://doi.org/10.1053/j.gastro.2011.10.
001 Epub 2011 Oct 14. PMID: 22001864. 
6. Chouraki V, Savoye G, Dauchet L, 
Vernier-Massouille G, Dupas JL, Merle 
V, Laberenne JE, Salomez JL, Lerebours 
E, Turck D, Cortot A, Gower-Rousseau 
C, Colombel JF. The changing pattern of 
Crohn's disease incidence in northern 
France: a continuing increase in the 10- 
to 19-year-old age bracket (1988-2007). 
Aliment Pharmacol Ther. 2011 
May;33(10):1133-42. 
https://doi.org/10.1111/j.1365-
2036.2011.04628.x. Epub 2011 Mar 16. 
PMID: 21488915. 
7. Kornfeld D, Cnattingius S, Ekbom A. 
Pregnancy outcomes in women with 
inflammatory bowel disease--a 
population-based cohort study. Am J 
Obstet Gynecol. 1997 Oct;177(4):942-6. 
https://doi.org/10.1016/S0002-
9378(97)70298-9 PMID: 9369849. 
8. Molnár T, Farkas K, Nagy F, Lakatos PL, 
Miheller P, Nyári T, Horváth G, Szepes Z, 
Marik A, Wittmann T. Pregnancy 
outcome in patients with inflammatory 
bowel disease according to the activity of 
the disease and the medical treatment: a 
case-control study. Scand J 
Gastroenterol. 2010 Nov;45(11):1302-6. 
https://doi.org/10.3109/00365521.2010.
503967  Epub 2010 Jul 5. PMID: 
20602569. 
9. Fonager K, Sørensen HT, Olsen J, 
Dahlerup JF, Rasmussen SN. 
Pregnancy outcome for women with 
Crohn's disease: a follow-up study based 
on linkage between national registries. 
Am J Gastroenterol. 1998 
Dec;93(12):2426-30. 
https://doi.org/10.1111/j.1572-
0241.1998.00698.x PMID: 9860403. 
10. Dominitz JA, Young JC, Boyko EJ. 
Outcomes of infants born to mothers with 
inflammatory bowel disease: a 
population-based cohort study. Am J 
Gastroenterol. 2002 Mar;97(3):641-8. 
https://doi.org/10.1111/j.1572-
0241.2002.05543.x. PMID: 11926208. 
11. Nørgård B, Fonager K, Sørensen HT, 
Olsen J. Birth outcomes of women with 
ulcerative colitis: a nationwide Danish 
cohort study. Am J Gastroenterol. 2000 
Nov;95(11):3165-70. 
https://doi.org/10.1111/j.1572-
0241.2000.03290.x PMID: 11095336. 
12. Porter RJ, Stirrat GM. The effects of 
inflammatory bowel disease on 
pregnancy: a case-controlled 
retrospective analysis. Br J Obstet 
Gynaecol. 1986 Nov;93(11):1124-31. 
https://doi.org/10.1111/j.1471-
0528.1986.tb08632.x PMID: 3778845. 
13. Getahun D, Fassett MJ, Longstreth GF, 
Koebnick C, Langer-Gould AM, 
Strickland D, Jacobsen SJ. Association 
between maternal inflammatory bowel 
disease and adverse perinatal outcomes. 
J Perinatol. 2014 Jun;34(6):435-40. 
https://doi.org/10.1038/jp.2014.41 Epub 
2014 Mar 20. PMID: 24651735. 
 Proceedings in Obstetrics and Gynecology, 2020;10(1):3 
Maternal IBD and adverse birth outcomes  14 
14. Kammerlander H, Nielsen J, Kjeldsen J, 
Knudsen T, Friedman S, Nørgård B. The 
Effect of Disease Activity on Birth 
Outcomes in a Nationwide Cohort of 
Women with Moderate to Severe 
Inflammatory Bowel Disease. Inflamm 
Bowel Dis. 2017 Jun;23(6):1011-1018. 
https://doi.org/10.1097/MIB.0000000000
001102 PMID: 28346274. 
15. Mahadevan U, Robinson C, Bernasko N, 
Boland B, Chambers C, Dubinsky M, 
Friedman S, Kane S, Manthey J, 
Sauberan J, Stone J, Jain R. 
Inflammatory Bowel Disease in 
Pregnancy Clinical Care Pathway: A 
Report from the American 
Gastroenterological Association 
IBD Parenthood Project Working Group. 
Am J Obstet Gynecol. 2019 
Apr;220(4):308-323. 
https://doi.org/10.1016/j.ajog.2019.02.02
7 PMID: 30948039. 
16. Nguyen GC, Boudreau H, Harris ML, 
Maxwell CV. Outcomes of obstetric 
hospitalizations among women with 
inflammatory bowel disease in the United 
States. Clin Gastroenterol Hepatol. 2009 
Mar;7(3):329-34. 
https://doi.org/10.1016/j.cgh.2008.10.02
2 Epub 2008 Oct 30. PMID: 19027089. 
17. Cornish J, Tan E, Teare J, Teoh TG, Rai 
R, Clark SK, Tekkis PP. A meta-analysis 
on the influence of inflammatory bowel 
disease on pregnancy. Gut. 2007 
Jun;56(6):830-7. 
https://doi.org/10.1136/gut.2006.108324 
Epub 2006 Dec 21. PMID: 17185356; 
PMCID: PMC1954859. 
18. Wispelwey BP, Sheiner E. Inflammatory 
bowel disease and preterm delivery. Arch 
Gynecol Obstet. 2013 Oct;288(4):725-
30. https://doi.org/10.1007/s00404-013-
2989-3 Epub 2013 Aug 10. PMID: 
23934241. 
19. Beaulieu DB, Kane S. Inflammatory 
bowel disease in pregnancy. World J 
Gastroenterol. 2011 Jun 14;17(22):2696-
701. 
https://doi.org/10.3748/wjg.v17.i22.2696 
PMID: 21734776; PMCID: 
PMC3122257. 
20. HCUP Nationwide Inpatient Sample 
(NIS).  Healthcare Cost and Utilization 
Project (HCUP). 1993-2008. Agency for 
Healthcare Research and Quality, 
Rockville, MD.   www.hcup-
us.ahrq.gov/overview.jsp   Accessed on 
1 August 2015 
21. The Center for Disease Control and 
Prevention. (2013) Preterm birth. 
Available at:  
http://www.cdc.gov/reproductivehealth/
maternalinfanthealth/pretermbirth.htm.  
Accessed on 28 February 2015 
22. U.S. National Library of Medicine. Small 
for Gestational Age.  Available at: 
http://www.nlm.nih.gov/medlineplus/enc
y/article/002302.htm.  Accessed on 6 
August 2015 
23. Bortoli A, Pedersen N, Duricova D, 
D'Inca R, Gionchetti P, Panelli MR, 
Ardizzone S, Sanroman AL, Gisbert JP, 
Arena I, Riegler G, Marrollo M, Valpiani 
D, Corbellini A, Segato S, Castiglione F, 
Munkholm P; European Crohn-Colitis 
Organisation (ECCO) Study Group of 
Epidemiologic Committee (EpiCom). 
Pregnancy outcome in inflammatory 
bowel disease: prospective European 
case-control ECCO-EpiCom study, 
2003-2006. Aliment Pharmacol Ther. 
2011 Oct;34(7):724-34. 
https://doi.org/10.1111/j.1365-
2036.2011.04794.x Epub 2011 Aug 4. 
Erratum in: Aliment Pharmacol Ther. 
2013 Aug;38(3):328. PMID: 21815900. 
 Proceedings in Obstetrics and Gynecology, 2020;10(1):3 
Maternal IBD and adverse birth outcomes  15 
24. Bröms G, Granath F, Linder M, 
Stephansson O, Elmberg M, Kieler H. 
Birth outcomes in women with 
inflammatory bowel disease: effects of 
disease activity and drug exposure. 
Inflamm Bowel Dis. 2014 
Jun;20(6):1091-8. 
https://doi.org/10.1097/MIB.0000000000
000060 PMID: 24810137. 
25. Stephansson O, Larsson H, Pedersen L, 
Kieler H, Granath F, Ludvigsson JF, 
Falconer H, Ekbom A, Sørensen HT, 
Nørgaard M. Congenital abnormalities 
and other birth outcomes in children born 
to women with ulcerative colitis in 
Denmark and Sweden. Inflamm Bowel 
Dis. 2011 Mar;17(3):795-801. 
https://doi.org/10.1002/ibd.21369 PMID: 
20564537.  
26. Stephansson O, Larsson H, Pedersen L, 
Kieler H, Granath F, Ludvigsson JF, 
Falconer H, Ekbom A, Sørensen HT, 
Nørgaard M. Crohn's disease is a risk 
factor for preterm birth. Clin 
Gastroenterol Hepatol. 2010 
Jun;8(6):509-15 
https://doi.org/10.1016/j.cgh.2010.02.01
4 Epub 2010 Mar 2. PMID: 20202483. 
27. Logan RF, Kay CR. Oral contraception, 
smoking and inflammatory bowel 
disease--findings in the Royal College of 
General Practitioners Oral Contraception 




28. Vessey M, Jewell D, Smith A, Yeates D, 
McPherson K. Chronic inflammatory 
bowel disease, cigarette smoking, and 
use of oral contraceptives: findings in a 
large cohort study of women of 
childbearing age. Br Med J (Clin Res Ed). 
1986 Apr 26;292(6528):1101-3. 
https://doi.org/10.1136/bmj.292.6528.11
01 PMID: 3084016; PMCID: 
PMC1340036. 
29. Savoye G. Is preterm delivery in 
inflammatory bowel disease women part 
of the burden of innate immunity 




30. Hermon-Taylor J. Protagonist. 
Mycobacterium avium subspecies 
paratuberculosis is a cause of Crohn's 
disease. Gut. 2001 Dec;49(6):755-6. 
https://doi.org/10.1136/gut.49.6.755 
PMID: 11709506; PMCID: 
PMC1728545. 
31. Reddy D, Murphy SJ, Kane SV, Present 
DH, Kornbluth AA. Relapses of 
inflammatory bowel disease during 
pregnancy: in-hospital management and 
birth outcomes. Am J Gastroenterol. 
2008 May;103(5):1203-9. 
https://doi.org/10.1111/j.1572-
0241.2007.01756.x  Epub 2008 Apr 16. 
PMID: 18422816. 
32. Ekbom A, Daszak P, Kraaz W, Wakefield 
AJ. Crohn's disease after in-utero 
measles virus exposure. Lancet. 1996 
Aug 24;348(9026):515-7. 
https://doi.org/10.1016/S0140-
6736(96)04429-7 PMID: 8757154. 
33. Klement E, Cohen RV, Boxman J, 
Joseph A, Reif S. Breastfeeding and risk 
of inflammatory bowel disease: a 
systematic review with meta-analysis. 
Am J Clin Nutr. 2004 Nov;80(5):1342-52. 
https://doi.org/10.1093/ajcn/80.5.1342 
PMID: 15531685. 
34. Nasef NA, Ferguson LR. Inflammatory 
bowel disease and pregnancy: 
overlapping pathways. Transl Res. 2012 
Jul;160(1):65-83. 
https://doi.org/10.1016/j.trsl.2011.12.002 
Epub 2011 Dec 23. PMID: 22687963. 
35. Das KM. Relationship of extraintestinal 
involvements in inflammatory bowel 
disease: new insights into autoimmune 
pathogenesis. Dig Dis Sci. 1999 
Jan;44(1):1-13. 
https://doi.org/10.1023/A:102662952823
3  PMID: 9952216. 
 Proceedings in Obstetrics and Gynecology, 2020;10(1):3 
Maternal IBD and adverse birth outcomes  16 
36. Turkcapar N, Toruner M, Soykan I, 
Aydintug OT, Cetinkaya H, Duzgun N, 
Ozden A, Duman M. The prevalence of 
extraintestinal manifestations and HLA 
association in patients with inflammatory 
bowel disease. Rheumatol Int. 2006 
May;26(7):663-8 
https://doi.org/10.1007/s00296-005-
0044-9 Epub 2005 Sep 1. PMID: 
16136311. 
37. Mortensen LH. Socioeconomic inequality 
in birth weight and gestational age in 
Denmark 1996-2007: using a family-
based approach to explore alternative 
explanations. Soc Sci Med. 2013 
Jan;76(1):1-7. 
https://doi.org/10.1016/j.socscimed.2012
.08.021. Epub 2012 Sep 11. PMID: 
23026073. 
38. Heaman M, Kingston D, Chalmers B, 
Sauve R, Lee L, Young D. Risk factors 
for preterm birth and small-for-
gestational-age births among Canadian 
women. Paediatr Perinat Epidemiol. 
2013 Jan;27(1):54-61. 
https://doi.org/10.1111/ppe.12016 PMID: 
23215712. 
 
